Atomoxetine pharmacogenetics: Associations with pharmacokinetics, treatment response and tolerability

Pharmacogenomics

Volumn 16, Issue 13, 2015, Pages 1513-1520

  Brown, Jacob T ^a   Bishop, Jeffrey R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

ADHD; atomoxetine; CYP2D6; pharmacogenetics

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; NORADRENALIN TRANSPORTER; PAROXETINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT;

AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; GENETIC VARIABILITY; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE VARIATION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; GENETICS; GENOTYPE; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ATOMOXETINE HYDROCHLORIDE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; PHARMACOGENETICS; TREATMENT OUTCOME;

EID: 84941658089     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/PGS.15.93     Document Type: Review

References (51)

1. STRATTERA® (atomoxetine) [package insert]. Eli Lilly and Company, IN, USA (2015).
2. Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002-2010. Pediatrics 130(1), 23-31 (2012).
3. Cascade EF, Kalali AH, Feifel D. Strattera: ups, downs, and emerging uses. Psychiatry (Edgmont) 4(4), 23-25 (2007).
4. Du DT, Zhou EH, Goldsmith J, Nardinelli C, Hammad TA. Atomoxetine use during a period of FDA actions. Med. Care 50(11), 987-992 (2012).
5. Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat. 10(237), 1-14 (2008).
6. Boyle CA, Boulet S, Schieve LA et al. Trends in the prevalence of developmental disabilities in US children, 1997-2008. Pediatrics 127(6), 1034-1042 (2011).
7. Kessler RC, Adler L, Barkley R et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am. J. Psychiatry 163(4), 716-723 (2006).
8. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J. Am. Acad. Child Adolesc. Psychiatry 43(5), 559-567 (2004).
9. Wong DT, Threlkeld PG, Best KL, Bymaster FP. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J. Pharmacol. Exp. Ther. 222(1), 61-65 (1982).
10. Gehlert DR, Gackenheimer SL, Robertson DW. Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci. Lett. 157(2), 203-206 (1993).
11. Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol. Psychiatry 7(Suppl. 1), S23-S28 (2002).
12. Savill NC, Buitelaar JK, Anand E et al. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. CNS Drugs 29(2), 131-151 (2015).
13. Donnelly C, Bangs M, Trzepacz P et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 48(2), 176-185 (2009).
14. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatry 25(5), 534-553 (2013).
15. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108(5), E83 (2001).
16. Institute for Safe Medication Practices. Adverse drug events in children under age 18. http://www.ismp.org/quarterwatch/pdfs
17. Sauer JM, Ponsler GD, Mattiuz EL et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab. Dispos. 31(1), 98-107 (2003).
18. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab. Dispos. 30(3), 319-323 (2002).
19. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 41(2), 89-295 (2009).
20. The human cytochrome p450 allele nomenclature database. http://www.cypalleles.ki.se/cyp2d6.htm
21. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr. Drug Metab. 15(2), 218-232 (2014).
22. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008).
23. Leeder JS, Brown JT, Soden SE. Individualizing the use of medications in children: making Goldilocks happy. Clin. Pharmacol. Ther. 96(3), 304-306 (2014).
24. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J. Clin. Pharmacol. 25(4), 296-301 (1985).
25. Cui YM, Teng CH, Pan AX et al. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6∗10 allele. Br. J. Clin. Pharmacol. 64(4), 445-449 (2007).
26. Matsui A, Azuma J, Witcher JW et al. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6∗10/∗10 genotype in healthy Japanese men. J. Clin. Pharmacol. 52(3), 388-403 (2012).
27. Witcher JW, Kurtz D, Heathman M, Sauer JM, Smith BP. Population pharmacokinetic analysis of atomoxetine in pediatric patients [abstract]. Clin. Pharmacol. Ther. 75, 46 (2004).
28. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 46(2), 242-251 (2007).
29. Brown JT, Abdel-Rahman SM, Van Haandel L, Gaedigk A, Leeder JS. Single dose pharmacokinetics of atomoxetine in children with attention deficit hyperactivity disorder stratified by their CYP2D6 activity score (abstract). Clin. Pharmacol. Ther. 97(S1), S97 (2015).
30. de Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J. Clin. Psychopharmacol. 27(3), 241-245 (2007).
31. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J. Clin. Pharmacol. 42(11), 1219-1227 (2002).
32. Paulzen M, Clement HW, Gründer G. Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int. J. Neuropsychopharmacol. 11(2), 289-291 (2008).
33. Chamberlain SR, Robbins TW. Noradrenergic modulation of cognition: therapeutic implications. J. Psychopharmacol. 27(8), 694-718 (2013).
34. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry 53(5), 448-455 (1996).
35. Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol. Biochem. Behav. 99(2), 211-216 (2011).
36. Kesner RP, Churchwell JC. An analysis of rat prefrontal cortex in mediating executive function. Neurobiol. Learn Mem. 96(3), 417-431 (2011).
37. Ago Y, Umehara M, Higashino K et al. Atomoxetine-induced increases in monoamine release in the prefrontal cortex are similar in spontaneously hypertensive rats and Wistar-Kyoto rats. Neurochem. Res. 39(5), 825-832 (2014).
38. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27(5), 699-711 (2002).
39. Atkinson M, Hollis C. NICE guideline: attention deficit hyperactivity disorder. Arch. Dis. Child Educ. Pract. Ed. 95(1), 24-27 (2010).
40. Pliszka SR, Crismon ML, Hughes CW et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 45(6), 642-657 (2006).
41. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J. Clin. Psychiatry 71(6), 754-763 (2010).
42. Arnold LE, Lindsay RL, López FA et al. Treating attentiondeficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 120(5), 1100-1106 (2007).
43. Wietecha LA, Wang S, Saylor KE, Day KA, Wu SH, Kelsey D. Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: treatment with atomoxetine. Clin. Pediatr. (Phila), 54(2), 164-173 (2015).
44. Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J. Psychopharmacol. 28(3), 204-211 (2014).
45. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J. Am. Acad. Child Adolesc. Psychiatry 48(5), 511-518 (2009).
46. Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW, Buitelaar JK. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur. Neuropsychopharmacol. 18(2), 79-86 (2008).
47. ter Laak MA, Temmink HA, Koeken A et al. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity. Pediatr. Neurol. 43(3), 159-162.
48. Ramoz N, Boni C, Downing AM et al. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology 34(9), 2135-2142 (2009).
49. Yang L, Qian Q, Liu L, Li H, Faraone SV, Wang Y. Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J. Neural. Transm. 120(7), 1127-1133 (2013).
50. Dutch pharmacogenetics working group guideline for atomoxetine and CYP2D6. https://www.pharmgkb.org/guideline/PA166104989
51. CPIC: Clinical Pharmacogenetics Implementation consortium. https://www.pharmgkb.org/page/cpic